| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of Monoethylglycinexylidide is not a specific receptor, as the compound is a metabolite rather than a therapeutic agent. The compound is formed from lidocaine by oxidative N-deethylation catalyzed by cytochrome P-450 enzymes, primarily CYP3A4 and CYP1A2, in the liver. MEGX itself has some pharmacological activity, including local anesthetic effects similar to lidocaine, although it is less potent than the parent compound. The compound's primary use is as a marker of liver function, as the rate of MEGX formation from lidocaine reflects hepatic metabolic capacity. MEGX may also interact with sodium channels, similar to lidocaine, but with lower affinity.
|
|---|---|
| ln Vitro |
In vitro studies on Monoethylglycinexylidide are focused on its role as a metabolite of lidocaine and its use as a marker of liver function. The compound is formed from lidocaine by oxidative N-deethylation in liver microsomes. In vitro metabolism studies using human liver microsomes or recombinant CYP enzymes demonstrate that MEGX formation is primarily catalyzed by CYP3A4 and CYP1A2. The compound can also be used as a substrate in enzyme assays to measure CYP450 activity. No specific biological activity data, such as IC50 or EC50 values, have been reported for MEGX as a pharmacological agent. The compound's local anesthetic activity is significantly less than that of lidocaine.In cell-based assays, Monoethylglycinexylidide could be used to study the metabolism of lidocaine or the effects of MEGX on cellular function. Hepatocytes (primary human hepatocytes or HepG2 cells) are cultured in appropriate medium and treated with lidocaine (0.1-100 µM) for 1-24 hours. MEGX formation in culture supernatants is measured by HPLC or LC-MS/MS. The effects of MEGX on cell viability, sodium channel function, or other cellular processes could be assessed. However, no specific data have been reported for MEGX in cell-based assays. The compound is primarily a metabolite and is used as a marker rather than as a pharmacological agent.
|
| ln Vivo |
In in vivo animal studies, Monoethylglycinexylidide is used as a marker of liver function. The MEGX test involves the administration of lidocaine (1 mg/kg, intravenous) followed by measurement of MEGX levels in blood samples at 15-30 minutes after administration. The rate of MEGX formation reflects hepatic cytochrome P-450 activity and liver blood flow. In animal models of liver disease, MEGX formation is reduced, consistent with impaired liver function. The MEGX test is used in preclinical studies to assess liver function in rodents, dogs, and other species. Specific study protocols vary depending on the species and experimental design.
|
| Enzyme Assay |
In vitro enzyme assays for Monoethylglycinexylidide are performed using human liver microsomes or recombinant CYP enzymes (CYP3A4, CYP1A2). The assay is conducted in microcentrifuge tubes in a total volume of 200 µL. Reaction buffer consists of 100 mM potassium phosphate buffer (pH 7.4), 10 mM MgCl2, and 1 mM NADPH. Lidocaine (10-100 µM, substrate) is pre-incubated with microsomes (0.5-1 mg/mL protein) or recombinant CYP enzymes for 5 minutes at 37°C. The reaction is initiated by adding NADPH and incubated for 10-30 minutes at 37°C. The reaction is terminated by adding 50 µL of ice-cold acetonitrile containing an internal standard. Samples are centrifuged at 10,000 × g for 10 minutes, and the supernatant is analyzed for MEGX formation by HPLC with UV detection or LC-MS/MS. The amount of MEGX is quantified using a standard curve. Enzyme activity is expressed as pmol MEGX formed per mg protein per minute. Positive controls include known CYP3A4 substrates such as midazolam.
|
| Cell Assay |
For in vitro cell-based assays, primary human hepatocytes are cultured in Williams E medium with supplements at 37°C in 5% CO2. Cells are seeded in 24-well plates at 5 × 10^5 cells/well and allowed to attach for 24 hours. Lidocaine is added at concentrations of 1, 10, 50, and 100 µM, and cells are incubated for 1, 2, 4, 8, and 24 hours. Culture supernatants are collected, and MEGX levels are measured by LC-MS/MS. For cytotoxicity assessment, hepatocytes are treated with MEGX (1-100 µM) for 24 hours, and cell viability is assessed using the MTT assay. Data are expressed as MEGX concentration (µM) or as percentage of control viability.
|
| Animal Protocol |
In vivo animal studies for the MEGX test are performed in male Sprague-Dawley rats (200-250 g) or other species. Rats are anesthetized with isoflurane, and a catheter is placed in the femoral vein for drug administration and blood sampling. Lidocaine (1-2 mg/kg) is administered intravenously as a bolus. Blood samples (0.2-0.5 mL) are collected at 0, 5, 10, 15, 30, 45, and 60 minutes after lidocaine administration. Plasma is separated by centrifugation, and MEGX levels are measured by HPLC or LC-MS/MS. The MEGX concentration at 15 minutes (MEGX15) is used as the primary endpoint. In models of liver disease (e.g., CCl4-induced cirrhosis, bile duct ligation, or partial hepatectomy), MEGX formation is reduced compared to healthy controls. The MEGX test is also used in dogs and other large animal models. Data are expressed as MEGX concentration (ng/mL or µM) and compared between treatment groups.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of monoethylglycyl dimethylamine include glycyl dimethylamine and 3-hydroxymonoethylglycyl dimethylamine. Monoethylglycyl dimethylamine is a known metabolite of lidocaine. |
| References | |
| Additional Infomation |
Monoethylglycyl dimethylamine is an amino acid amide composed of 2,6-dimethylaniline and N-ethylglycine; it is the active metabolite of lidocaine, generated by oxidative deethylation. It can be used as a liver function indicator and is also a drug metabolite.
|
| Molecular Formula |
C12H18N2O
|
|---|---|
| Molecular Weight |
206.28
|
| Exact Mass |
206.142
|
| CAS # |
7728-40-7
|
| Related CAS # |
Monoethylglycinexylidide hydrochloride;7729-94-4;Monoethylglycinexylidide-d6;1216698-89-3;Monoethylglycinexylidide-d6 hydrochloride;2748541-96-8
|
| PubChem CID |
24415
|
| Appearance |
White to off-white solid
|
| Density |
1.047g/cm3
|
| Boiling Point |
335.6ºC at 760 mmHg
|
| Melting Point |
242-245ºC
|
| Flash Point |
127.8ºC
|
| Index of Refraction |
1.553
|
| LogP |
2.315
|
| tPSA |
41.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(=C(C=CC=C1C)C)NC(=O)CNCC
|
| InChi Key |
WRMRXPASUROZGT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H18N2O/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3/h5-7,13H,4,8H2,1-3H3,(H,14,15)
|
| Chemical Name |
N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide
|
| Synonyms |
L 86 L-86 L86Monoethylglycinexylidide Ethylglycylxylidide BRN 2417108
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~484.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (24.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (24.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (24.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8478 mL | 24.2389 mL | 48.4778 mL | |
| 5 mM | 0.9696 mL | 4.8478 mL | 9.6956 mL | |
| 10 mM | 0.4848 mL | 2.4239 mL | 4.8478 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.